TBPH
Theravance Biopharma, Inc. NASDAQ Listed May 16, 2014$17.03
Mkt Cap $876.9M
52w Low $8.33
68.5% of range
52w High $21.03
50d MA $15.81
200d MA $16.03
P/E (TTM)
8.0x
EV/EBITDA
-109.8x
P/B
2.9x
Debt/Equity
0.2x
ROE
20.6%
P/FCF
3.9x
RSI (14)
—
ATR (14)
—
Beta
0.17
50d MA
$15.81
200d MA
$16.03
Avg Volume
633.1K
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Ugland House · George Town, CA KY1-1104 · KY
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 16.94 | +0.0% | +0.5% | -0.1% | — | — | — | — |
| Mar 19, 2026 | AMC | 0.44 | 0.06 | -86.4% | 14.01 | +0.4% | +2.3% | +2.9% | +1.0% | +2.6% | -0.7% | — |
| Nov 10, 2025 | AMC | -0.03 | 0.04 | +233.3% | 15.08 | +3.2% | +22.7% | -3.9% | +1.0% | -3.1% | +3.7% | — |
| Aug 12, 2025 | AMC | -0.14 | -0.08 | +42.9% | 11.92 | +0.6% | +4.2% | +4.2% | +1.6% | +3.5% | -1.2% | — |
| May 8, 2025 | AMC | -0.11 | -0.17 | -54.5% | 9.90 | -9.3% | -9.3% | -2.0% | +1.2% | -5.6% | +8.7% | — |
| Feb 26, 2025 | AMC | -0.05 | -0.05 | +0.0% | 9.08 | +8.8% | +2.1% | +0.9% | -2.1% | -0.5% | +6.8% | — |
| Nov 12, 2024 | AMC | -0.10 | -0.06 | +40.0% | 8.91 | +6.3% | +8.6% | -1.1% | -0.5% | -0.3% | +4.5% | — |
| Aug 5, 2024 | AMC | -0.09 | -0.13 | -44.4% | 9.59 | -9.8% | -18.4% | +0.0% | -1.9% | -0.3% | +7.6% | — |
| May 13, 2024 | AMC | -0.19 | -0.09 | +52.6% | 9.58 | +1.7% | -2.0% | +4.9% | -2.5% | -3.2% | -2.0% | — |
| Feb 26, 2024 | AMC | 0.04 | 0.03 | -14.3% | 9.23 | +0.7% | +5.0% | -3.0% | +0.7% | -0.3% | -3.6% | — |
| Nov 7, 2023 | AMC | -0.10 | -0.01 | +90.0% | 9.73 | -3.4% | +5.3% | -1.8% | +0.3% | +1.0% | +1.0% | — |
| Aug 7, 2023 | AMC | -0.16 | -0.13 | +18.8% | 9.83 | +3.0% | -0.9% | +4.7% | -1.8% | -0.5% | +1.0% | — |
| May 8, 2023 | AMC | -0.27 | -0.24 | +11.1% | 11.33 | +5.7% | +0.4% | +0.8% | -3.3% | +1.9% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | B. Riley Securities | Maintains | Neutral → Neutral | — | $16.10 | $16.22 | +0.7% | +2.9% | +0.2% | -0.3% | -1.2% | +0.9% |
| Mar 23 | TD Cowen | Maintains | Hold → Hold | — | $14.33 | $14.73 | +2.8% | +2.9% | +1.0% | +2.6% | -0.7% | -0.7% |
| Mar 20 | BTIG | Maintains | Buy → Buy | — | $14.01 | $14.07 | +0.4% | +2.3% | +2.9% | +1.0% | +2.6% | -0.7% |
| Mar 5 | Oppenheimer | Downgrade | Outperform → Perform | — | $13.67 | $13.50 | -1.2% | -0.7% | -0.1% | +3.2% | +0.2% | -1.6% |
| Mar 4 | B. Riley Securities | Downgrade | Buy → Neutral | — | $13.96 | $13.37 | -4.2% | -2.1% | -0.7% | -0.1% | +3.2% | +0.2% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.96 | $13.37 | -4.2% | -2.1% | -0.7% | -0.1% | +3.2% | +0.2% |
| Mar 3 | BTIG | Maintains | Buy → Buy | — | $18.95 | $14.27 | -24.7% | -26.3% | -2.1% | -0.7% | -0.1% | +3.2% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.25 | $18.68 | +2.4% | +3.8% | -26.3% | -2.1% | -0.7% | -0.1% |
| Feb 3 | BTIG | Maintains | Buy → Buy | — | $19.83 | $19.91 | +0.4% | +0.8% | +0.5% | -2.5% | +4.6% | -4.8% |
| Nov 26 | BTIG | Maintains | Buy → Buy | — | $18.94 | $19.84 | +4.8% | +5.4% | +1.7% | -3.4% | -6.0% | +2.5% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.08 | $15.57 | +3.2% | +22.7% | -3.9% | +1.0% | -3.1% | +3.7% |
| Jun 27 | BTIG | Maintains | Buy → Buy | — | $10.73 | $10.95 | +2.1% | +4.6% | -1.7% | -1.1% | +1.3% | +0.9% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.08 | $9.88 | +8.8% | +2.1% | +0.9% | -2.1% | -0.5% | +6.8% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.86 | $8.84 | -0.2% | +1.2% | +1.2% | +2.1% | +0.9% | -2.1% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.14 | $8.19 | +0.6% | -0.2% | +1.5% | +0.4% | -0.7% | -2.4% |
| Aug 6 | TD Cowen | Maintains | Hold → Hold | — | $9.59 | $8.65 | -9.8% | -18.4% | +0.0% | -1.9% | -0.3% | +7.6% |
| Aug 6 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $9.59 | $8.65 | -9.8% | -18.4% | +0.0% | -1.9% | -0.3% | +7.6% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.59 | $8.65 | -9.8% | -18.4% | +0.0% | -1.9% | -0.3% | +7.6% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.41 | $8.33 | -1.0% | -1.4% | +2.4% | +1.5% | -1.0% | +1.2% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.58 | $9.74 | +1.7% | -2.0% | +4.9% | -2.5% | -3.2% | -2.0% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.83 | $10.12 | +3.0% | -0.9% | +4.7% | -1.8% | -0.5% | +1.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.33 | $11.98 | +5.7% | +0.4% | +0.8% | -3.3% | +1.9% | -0.4% |
| Nov 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $11.22 | $11.30 | +0.7% | +1.1% | -4.3% | -4.2% | +2.1% | -3.2% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.05 | $10.36 | +3.1% | +3.1% | +5.2% | +3.6% | -0.2% | +0.2% |
| Jul 25 | Morgan Stanley | Maintains | Underweight → Underweight | — | $9.69 | $9.59 | -1.0% | -4.6% | -3.0% | -0.2% | -0.9% | -0.8% |
| Mar 2 | Morgan Stanley | Maintains | Underweight → Underweight | — | $10.49 | $10.63 | +1.3% | -2.3% | -3.3% | -3.0% | +0.7% | +1.1% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.11 | $9.46 | +3.8% | +9.0% | +3.1% | -1.7% | +4.2% | -2.3% |
| Nov 5 | JP Morgan | Upgrade | Underweight → Neutral | — | $8.50 | $8.95 | +5.3% | +6.5% | -1.1% | -3.1% | -1.5% | -2.1% |
| Sep 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.77 | $6.89 | +1.8% | +1.3% | +3.6% | -3.2% | +3.2% | +1.7% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.77 | $6.89 | +1.8% | +1.3% | +3.6% | -3.2% | +3.2% | +1.7% |
| Sep 16 | Morgan Stanley | Maintains | Underweight → Underweight | — | $6.77 | $6.89 | +1.8% | +1.3% | +3.6% | -3.2% | +3.2% | +1.7% |
| Aug 25 | Morgan Stanley | Downgrade | Overweight → Underweight | — | $9.24 | $9.21 | -0.3% | -5.8% | -5.4% | +0.0% | +2.1% | -1.2% |
| Aug 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.17 | $10.27 | -27.5% | -34.8% | -5.8% | -5.4% | +0.0% | +2.1% |
| Aug 24 | SVB Leerink | Maintains | Outperform → Outperform | — | $14.17 | $10.27 | -27.5% | -34.8% | -5.8% | -5.4% | +0.0% | +2.1% |
| Aug 24 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $14.17 | $10.27 | -27.5% | -34.8% | -5.8% | -5.4% | +0.0% | +2.1% |
| Aug 24 | Needham | Maintains | Buy → Buy | — | $14.17 | $10.27 | -27.5% | -34.8% | -5.8% | -5.4% | +0.0% | +2.1% |
| Aug 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $13.63 | $14.13 | +3.7% | -4.6% | +3.5% | -3.3% | +0.0% | +4.0% |
| Jul 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.62 | $13.70 | +0.6% | -2.6% | +0.8% | +5.6% | -1.8% | -0.8% |
| Jun 28 | SVB Leerink | Maintains | Outperform → Outperform | — | $15.60 | $15.80 | +1.3% | +0.8% | -4.6% | -3.3% | -0.8% | -0.3% |
| May 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $18.87 | $19.02 | +0.8% | -0.8% | +0.0% | -1.6% | -1.9% | -2.6% |
| May 5 | Needham | Maintains | Buy → Buy | — | $19.88 | $19.85 | -0.2% | -1.6% | -0.9% | +1.9% | -2.8% | -3.4% |
| May 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $19.88 | $19.85 | -0.2% | -1.6% | -0.9% | +1.9% | -2.8% | -3.4% |
| Apr 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $20.41 | $20.47 | +0.3% | -1.4% | +2.2% | +0.9% | +3.9% | +1.0% |
| Mar 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.57 | $16.77 | +1.2% | +5.5% | +5.2% | +2.9% | -0.8% | +3.7% |
| Feb 24 | SVB Leerink | Maintains | Outperform → Outperform | — | $17.65 | $19.14 | +8.4% | -0.9% | -1.0% | -4.3% | +5.5% | +5.2% |
| Dec 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.74 | $19.87 | +0.7% | -3.5% | +0.9% | +1.2% | -2.3% | +0.3% |
| Nov 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $19.48 | $18.73 | -3.9% | -13.8% | +6.4% | +4.6% | -1.8% | -4.9% |
| Oct 14 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $17.28 | $19.40 | +12.3% | +9.6% | -2.9% | +0.7% | +0.9% | -1.6% |
| Aug 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.96 | $18.04 | +0.4% | -2.3% | -2.2% | -2.0% | +0.7% | -1.3% |
| Aug 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $17.96 | $18.04 | +0.4% | -2.3% | -2.2% | -2.0% | +0.7% | -1.3% |
No insider trades available.
8-K · 2.02
!! High
Theravance Biopharma, Inc. -- 8-K 2.02: Earnings Results
Theravance Biopharma reported financial results through a press release, with details provided in the exhibit to assess operational performance and investor impact.
May 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Resolution of all Hatch-Waxman litigation for YUPELRI removes legal uncertainty and allows the company to fully capitalize on this respiratory drug's market potential without ongoing patent disputes.
Mar 30
8-K
Unknown — 8-K Filing
Theravance Biopharma's full-year 2025 results indicate operational progress; investors should monitor revenue trends and pipeline developments to assess whether the biotech firm can achieve profitability and justify its current valuation.
Mar 19
8-K · 7.01
! Medium
Theravance Biopharma, Inc. -- 8-K 7.01: Regulation FD Disclosure
Theravance disclosed material non-public information to select parties, requiring broad disclosure to maintain fair access, which could signal pending news affecting stock valuation.
Mar 3
Data updated apr 27, 2026 4:06am
· Source: massive.com